LGALS3 and metabolic dysfunction-associated steatotic liver disease: Further, Lgals3 ablation enhances liver steatosis, but attenuates inflammation and IL-33 dependant fibrosis in mouse model of non-alcoholic fatty liver disease (NAFLD) (Jeftic et al., 2015), and enhances bile duct damage and liver fibrosis in xenobiotic induced primary biliary cholangitis (PBC) (Arsenijevic et al., 2016).